QNSWMJYOGMUVGO-REWXTUPXSA-N
- Product Name
- QNSWMJYOGMUVGO-REWXTUPXSA-N
- CAS No.
-
87725-72-2
- Chemical Name
- QNSWMJYOGMUVGO-REWXTUPXSA-N
- Synonyms
- QNSWMJYOGMUVGO-REWXTUPXSA-N
- CBNumber
- CB53408547
- Molecular Formula
- C24H35ClN2O5
- Formula Weight
- 466.9981
- MOL File
- 87725-72-2.mol
Hazard and Precautionary Statements (GHS)
N-Bromosuccinimide Price
Medical Isotopes, Inc.
- Product number
- 62219
- Product name
- TrandolaprilHCl
- Packaging
- 5mg
- Price
- $650
- Updated
- 2021/12/16
Medical Isotopes, Inc.
- Product number
- 62219
- Product name
- TrandolaprilHCl
- Packaging
- 25mg
- Price
- $1095
- Updated
- 2021/12/16
QNSWMJYOGMUVGO-REWXTUPXSA-N Chemical Properties,Usage,Production
Uses
Trandolapril Hydrochloride is an antihypertensive. Angiotensin converting enzyme (ACE) inhibitor.
in vivo
Trandolapril hydrochloride (3 mg/kg/day; p.o.; 7 d) reduces renal fibrosis in obstructive nephropathy in mice, by inhibiting renal interstitial matrix expression and myofibroblast activation, decreasing renal proinflammatory cytokine RANTES and TNF-α level[2].
Trandolapril hydrochloride (0.3 mg/kg/day; p.o.; 4 weeks) improves arterial mechanics in rats, prevents arterial hypertrophy, collagen and cellular fibronectin accumulation[3].
randolapril (0.3 mg/kg/day; p.o.; 4 months) exhibits a chronic anti-hypertension effects in rats, results in blood pressure decreasing[3].
Trandolapril hydrochloride (0.25 mg/kg; p.o.; twice a day; 4 months) inhibits Atherosclerosis in the Watanabe Heritable Hyperlipidemic Rabbit[4].
| Animal Model: | UUD (unilateral ureteral obstruction) model in Male CD-1 mice (18-22 g)[2] |
| Dosage: | 3 mg/kg |
| Administration: | Oral gavage; daily, for 7 days |
| Result: | Resulted in renal interstitial matrix expression (including fibronectin, type I, and type III collagen) decreasing, and inhibited myofibroblast activation by surprising a-smooth muscle actin (a-SMA) expression, decreased the RANTES (regulated on activation, normal T cell expressed and secreted) and TNF-α level.
|
| Animal Model: | SHR model (spontaneously hypertensive rats, 4-week-old)[3] |
| Dosage: | 0.3 mg/kg |
| Administration: | Oral gavage; daily for 4 weeks |
| Result: | Reduced collagen content in the aortic media and increased ariterial distensibility up to about 80%.
|
| Animal Model: | Watanabe heritable hyperlipidemic rabbit (3 months old)[4] |
| Dosage: | 0.25 mg/kg |
| Administration: | Oral gavage; twice a day; 9 months |
| Result: | Decreased in atherosclerotic involvement of the intimal surface, and also decreased cholesterol content in descending thoracic aorta.
|
QNSWMJYOGMUVGO-REWXTUPXSA-N Preparation Products And Raw materials
Raw materials
Preparation Products
QNSWMJYOGMUVGO-REWXTUPXSA-N Suppliers
- Tel
- +17819995354
- Email
- marketing@targetmol.com
- Country
- United States
- ProdList
- 19962
- Advantage
- 58
87725-72-2, QNSWMJYOGMUVGO-REWXTUPXSA-NRelated Search:
QNSWMJYOGMUVGO-REWXTUPXSA-N
87725-72-2